Advertisement

Topics

FDA Approves AstraZeneca’s Faslodex for the Treatment of Advanced Breast Cancer in Combination with Abemaciclib

10:32 EST 15 Nov 2017 | Speciality Pharma Journal

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a new indication for FASLODEX® (fulvestrant), expanding the indication to include use with abemaciclib, a CDK4/6 inhibitor, for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer (MBC) in women with …

Original Article: FDA Approves AstraZeneca’s Faslodex for the Treatment of Advanced Breast Cancer in Combination with Abemaciclib

NEXT ARTICLE

More From BioPortfolio on "FDA Approves AstraZeneca’s Faslodex for the Treatment of Advanced Breast Cancer in Combination with Abemaciclib"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...